Screener
ADMA Biologics ADMA Plasma Collection Centers — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| (in thousands) | ADMA Bio Manufacturing | Plasma Collection Centers | Total |
|---|---|---|---|
| Revenues | $$123,637 | $723 | 124,360 |
| Cost of product revenue | 37,564 | 554 | 38,118 |
| Research and development | 6,014 | - | 6,014 |
| Plasma center operating expenses | - | 1,026 | 1,026 |
| Gain on sale of plasma centers | - | - | - |
| Selling, marketing and distribution | 7,634 | - | 7,634 |
| Depreciation and amortization expense | 1,281 | 499 | 1,780 |
| General and administrative expense | 8,340 | - | 8,340 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's plasma collection centers — research and development expense?
- ADMA Biologics (ADMA) reported plasma collection centers — research and development expense of $0 in Q2 2026.
- What does plasma collection centers — research and development expense mean?
- Captures expenditures dedicated to improving plasma collection technologies, donor retention processes, or operational efficiencies within the collection centers. While these centers are primarily operational, R&D spending here reflects investment in long-term process innovation. It indicates the company's commitment to optimizing the upstream supply chain.
Ask your AI about ADMA Biologics's plasma collection centers — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude